CA2185448A1 - Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents - Google Patents
Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agentsInfo
- Publication number
- CA2185448A1 CA2185448A1 CA002185448A CA2185448A CA2185448A1 CA 2185448 A1 CA2185448 A1 CA 2185448A1 CA 002185448 A CA002185448 A CA 002185448A CA 2185448 A CA2185448 A CA 2185448A CA 2185448 A1 CA2185448 A1 CA 2185448A1
- Authority
- CA
- Canada
- Prior art keywords
- derivative
- epithelial cell
- cancer
- subject
- lipoxygenase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21207494A | 1994-03-14 | 1994-03-14 | |
US08/212,074 | 1994-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2185448A1 true CA2185448A1 (en) | 1995-09-21 |
Family
ID=22789451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002185448A Abandoned CA2185448A1 (en) | 1994-03-14 | 1995-03-14 | Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0750496A1 (de) |
AU (1) | AU698313B2 (de) |
CA (1) | CA2185448A1 (de) |
WO (1) | WO1995024894A2 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
DE19624704A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalkansäureamide |
US6451816B1 (en) | 1997-06-20 | 2002-09-17 | Klinge Pharma Gmbh | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
DE19756261A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide |
DE19756212A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
DE19756236A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
DE19756235A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide |
US6903118B1 (en) | 1997-12-17 | 2005-06-07 | Klinge Pharma Gmbh | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides |
EP1031564A1 (de) | 1999-02-26 | 2000-08-30 | Klinge Pharma GmbH | Hemmer der Nicotinamidmonononukleotide-Bildung und deren Verwendung zur Krebstherapie |
US6756399B2 (en) | 2001-06-29 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents |
GB0410103D0 (en) * | 2004-05-06 | 2004-06-09 | Biolipox Ab | New method |
WO2010124283A2 (en) | 2009-04-24 | 2010-10-28 | The Jackson Laboratory | Methods and compositions relating to hematologic malignancies |
CA2883879A1 (en) * | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5008294A (en) * | 1985-02-11 | 1991-04-16 | Chemex Pharmaceuticals, Inc. | Methods of treating tumors with compositions of catecholic butanes |
US4554276A (en) * | 1983-10-03 | 1985-11-19 | Pfizer Inc. | 2-Amino-5-hydroxy-4-methylpyrimidine derivatives |
US4880637A (en) * | 1985-02-11 | 1989-11-14 | Chemex Pharmaceuticals, Inc. | Compositions of catecholic butanes with zinc |
GB8619433D0 (en) * | 1986-08-08 | 1986-09-17 | Lilly Industries Ltd | Pharmaceutical compounds |
JPH01501791A (ja) * | 1986-11-19 | 1989-06-22 | ケメックス ファーマシューティカルズ,インコーポレイティド | 薬理学的に活性な化合物およびそれらの混合物、有機組成物および金属塩類 |
CA1321349C (en) * | 1986-11-21 | 1993-08-17 | Robert Zimmerman | Therapeutic combination of free-radical scavenger or metabolic inhibitor and biologically active protein |
GB9012252D0 (en) * | 1990-06-01 | 1990-07-18 | Lilly Industries Ltd | Pharmaceutical compounds |
GB9025514D0 (en) * | 1990-11-23 | 1991-01-09 | Wellcome Found | Anti-inflammatory compounds |
US5409690A (en) * | 1993-06-23 | 1995-04-25 | Chemex Pharmaceuticals, Inc. | Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol |
-
1995
- 1995-03-14 AU AU22722/95A patent/AU698313B2/en not_active Ceased
- 1995-03-14 WO PCT/US1995/003337 patent/WO1995024894A2/en not_active Application Discontinuation
- 1995-03-14 EP EP95916100A patent/EP0750496A1/de not_active Withdrawn
- 1995-03-14 CA CA002185448A patent/CA2185448A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1995024894A2 (en) | 1995-09-21 |
AU2272295A (en) | 1995-10-03 |
AU698313B2 (en) | 1998-10-29 |
EP0750496A1 (de) | 1997-01-02 |
WO1995024894A3 (en) | 1995-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6071949A (en) | Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents | |
Seibert et al. | Distribution of COX-1 and COX-2 in normal and inflamed tissues | |
CA2185448A1 (en) | Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents | |
US6207700B1 (en) | Amide derivatives for antiangiogenic and/or antitumorigenic use | |
CA2614192C (en) | Use of docosahexaenoic glycerides for the treatment of tumoral diseases | |
AU2001251379B2 (en) | Method to inhibit lipoxygenase and cancer cell proliferation | |
JPH09510958A (ja) | 大腸ガンの化学的予防薬剤および化学的治療薬剤としての2−ヒドロキシ−5−フェニルアゾ安息香酸誘導体の使用 | |
WO1995024894A9 (en) | Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents | |
AU2001251379A1 (en) | Method to inhibit lipoxygenase and cancer cell proliferation | |
US7034058B2 (en) | Anti-tumor pharmaceutical composition comprising N-vanillyl fatty acid amide | |
KR20110042108A (ko) | 새로운 메틸렌디옥시 페놀 화합물 및 질병 치료에서 이들의 사용 | |
WO2009155070A2 (en) | Compositions and methods for treatment of inflammation and hyperkeratotic lesions | |
EP1148783B1 (de) | Umwandlung von cox-inhibierenden, nicht cox-2 selektiven inhibitoren in derivate von cox-2 selektiven inhibitoren | |
US6762182B1 (en) | Converting cox inhibition compounds that are not COX-2 selective inhibitors to derivatives that are COX-2 selective inhibitors | |
Heikkila et al. | Inactivation of superoxide dismutase by several thiocarbamic acid derivatives | |
AU604226B2 (en) | Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein | |
SK972013A3 (sk) | Použitie 5-karboxymetyl-3-merkapto-1,2,4-triazino-[5,6-b]indolov a farmaceutický prostriedok s ich obsahom | |
JP2014505729A (ja) | コレステロールの低減および心血管事象の低減のための、コレステロール吸収阻害剤(アゼチジノン)およびω3脂肪酸(EPA、DHA、DPA) | |
EP2958559A1 (de) | Verwendung einer omega-3-emulsion auf lipidbasis zum schutz von organen vor ischämischer läsion | |
TEICHER et al. | Modulation of [cis-diaminedichloroplatinum (ii) hyperthermia] therapy by inhibitors of arachidonic-Acid metabolism | |
Khanapure et al. | Perspectives and clinical significance of the biochemical and molecular pharmacology of eicosanoids | |
Horrobin | Summary Statement: Fatty Acids and Cancer | |
KR20160036490A (ko) | 중쇄 지방산을 포함하는 암치료용 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |